Anetumab ravtansine: Phase I data

Data from 147 evaluable patients with advanced solid tumors refractory to standard treatment in an open-label, dose-escalation, U.S. Phase I trial showed that the maximum tolerated dose (MTD) of IV

Read the full 304 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE